 |
 Video: What is a Stock Split?
|
|
|
| Repare Therapeutics is a precision medicine oncology company focused on the development of synthetic lethality (SL)-based therapies to patients with cancer. Using Co.'s SNIPRx platform, Co. is developing its pipeline of SL product candidates, including its primary product candidate, RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). Co. is also developing an inhibitor of polymerase theta, which is SL with multiple gene deficiencies found in tumors. According to our Repare Therapeutics stock split history records, Repare Therapeutics has had 0 splits. | |
|
Repare Therapeutics (RPTX) has 0 splits in our Repare Therapeutics stock split history database.
Looking at the Repare Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Repare Therapeutics shares, starting with a $10,000 purchase of RPTX, presented on a split-history-adjusted basis factoring in the complete Repare Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/22/2020 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$32.99 |
|
| End price/share: |
$3.30 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-90.00% |
|
| Average Annual Total Return: |
-45.08% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,000.64 |
|
| Years: |
3.84 |
|
|
|
|
|
